Unknown

Dataset Information

0

PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.


ABSTRACT: This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18-65 years to twice-daily PF-04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. Blood samples were collected at baseline and various posttreatment time points for assessments of PF-04447943 pharmacokinetics (PKs)/pharmacodynamics (PDs). Change from baseline in potential SCD-related biomarkers was evaluated. Of 30 patients, 15 received hydroxyurea and 28 completed the study. PF-04447943, with/without hydroxyurea, was generally well tolerated, with no treatment-related serious adverse events. Plasma PF-04447943 exposure was dose proportional. Twice-daily PF-04447943 25 mg significantly reduced the number and size of circulating monocyte-platelet and neutrophil-platelet aggregates and levels of circulating soluble E-selectin at day 29 vs. baseline (adjusted P < 0.15). PF-04447943 demonstrated PK/PD effects suggestive of inhibiting pathways that may contribute to vaso-occlusion. This study also provides guidance regarding biomarkers for future SCD studies.

SUBMITTER: Charnigo RJ 

PROVIDER: S-EPMC6440678 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.

Charnigo Robert J RJ   Beidler David D   Rybin Denis D   Pittman Debra D DD   Tan Beesan B   Howard Jo J   Michelson Alan D AD   Frelinger Andrew L AL   Clarke Nicholas N  

Clinical and translational science 20181231 2


This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18-65 years to twice-daily PF-04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. Blood samples were collected at baseline and various posttreatment time points for assessments of PF-04447943 pharmacokinetics (PKs)/pharmacodynamics (PDs). Change from baseline in potential SCD-related biomarkers was evaluated. Of 30 patients, 15 received  ...[more]

Similar Datasets

| S-EPMC4281101 | biostudies-literature
| S-EPMC4033106 | biostudies-literature
| S-EPMC6046510 | biostudies-literature
| S-EPMC7993274 | biostudies-literature
| S-EPMC3469756 | biostudies-literature
| S-EPMC8763618 | biostudies-literature
| S-EPMC4613944 | biostudies-literature
| S-EPMC7895451 | biostudies-literature
| S-EPMC5807869 | biostudies-literature
| S-EPMC4670789 | biostudies-literature